Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 52 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Coinfection, HIV Clear all
Completed Phase 1Phase 2 Interventional Results available

A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures

NCT01185028
View directory record Official record
Conditions
Hepatitis C Infection, HIV Infection
Interventions
Nitazoxanide With Pegylated Interferon And Ribavirin
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 99 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Oct 22, 2026, 4:45 AM EDT
Completed Phase 2 Interventional Results available

Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects

NCT00991289
View directory record Official record
Conditions
HIV Infection, Hepatitis C Infection
Interventions
Nitazoxanide (NTZ), Pegylated interferon alfa-2a (PEG), Ribavirin (RBV)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 22, 2026, 4:45 AM EDT
Completed Phase 4 Interventional Results available

Treatment of Acute Hepatitis C Virus in HIV Co-Infection

NCT00845676
View directory record Official record
Conditions
Hepatitis C, Human Immunodeficiency Virus, HIV Infections
Interventions
Pegylated interferon alfa-2a + Ribavirin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 18, 2020 · Synced Oct 22, 2026, 4:45 AM EDT
Completed Phase 2 Interventional

TBTC Study 23C: Pharmacokinetics of Intermittent Rifabutin and Isoniazid With Daily Efavirenz

NCT00023413
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Rifabutin, Efavirenz
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
20
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2012 · Synced Oct 22, 2026, 4:45 AM EDT
Completed Phase 4 Interventional Results available

Effects of Ledipasvir/Sofosbuvir on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF)

NCT03126370
View directory record Official record
Conditions
Hepatitis C, HIV Coinfection
Interventions
TDF with a boosted protease inhibitor, TAF with a boosted protease inhibitor, TAF with a boosted protease inhibitor and LDV/SOF
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 22, 2026, 4:45 AM EDT
Completed Not applicable Interventional Results available

Nurse Case Management to Improve Hepatitis C Care in HIV Co-infection

NCT02707991
View directory record Official record
Conditions
HIV, Hepatitis C, Chronic
Interventions
Nurse Case Management
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 2, 2019 · Synced Oct 22, 2026, 4:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Integrating HIV and Hepatitis C Screening in an Urban Emergency Department

NCT03252483
View directory record Official record
Conditions
Hepatitis C, Hiv, HIV/AIDS, HCV Coinfection, HIV/AIDS and Infections
Interventions
Bundled HCV/HIV Screening, HIV Screening
Other
Lead sponsor
New York City Health and Hospitals Corporation
Other
Eligibility
18 Years and older
Enrollment
478 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Oct 22, 2026, 4:45 AM EDT
Completed No phase listed Observational

Eliminating Hepatitis C Virus

NCT03401697
View directory record Official record
Conditions
Hepatitis C, HIV, Type2 Diabetes
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
52 participants
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Oct 22, 2026, 4:45 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.

NCT02032888
View directory record Official record
Conditions
Hepatitis C
Interventions
Daclatasvir, Sofosbuvir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
37
States / cities
Birmingham, Alabama • Beverly Hills, California • Long Beach, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2015 · Synced Oct 22, 2026, 4:45 AM EDT
Completed Phase 2 Interventional Results available

Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance

NCT00665353
View directory record Official record
Conditions
HIV-1 and Hepatitis C Co-Infection
Interventions
pioglitazone, peginterferon, ribavirin
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
8
States / cities
San Francisco, California • Chicago, Illinois • Newark, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 22, 2026, 4:45 AM EDT
Completed Phase 2 Interventional Results available

Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver Fibrosis

NCT01707472
View directory record Official record
Conditions
Liver Fibrosis, Hepatitis C, HIV, HIV/HCV Co-infection
Interventions
Simtuzumab
Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 5, 2019 · Synced Oct 22, 2026, 4:45 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults

NCT02071082
View directory record Official record
Conditions
HIV, HBV
Interventions
E/C/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
21
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 22, 2026, 4:45 AM EDT
Completed No phase listed Observational

HCV/HIV Coinfection: Antiviral Therapy and Fibrosis

NCT01423643
View directory record Official record
Conditions
HIV Infection, Hepatitis C
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 99 Years
Enrollment
1,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 24, 2016 · Synced Oct 22, 2026, 4:45 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 8 Weeks in Subjects With Chronic Genotype 1 HCV and HIV-1 Co-infection

NCT02480387
View directory record Official record
Conditions
Treatment of Hepatitis C
Interventions
Ledipasvir/Sofosbuvir FDC
Drug
Lead sponsor
Peter J. Ruane, M.D., Inc.
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2016 · Synced Oct 22, 2026, 4:45 AM EDT
Terminated Phase 2 Interventional Results available

Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals

NCT04272242
View directory record Official record
Conditions
HIV Infection, LTBI
Interventions
Dolutegravir (DTG), Isoniazid (INH), Rifapentine (RPT), Antiretroviral Therapy (ART), Pyridoxine (Vitamin B6)
Drug · Dietary Supplement
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
San Francisco, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 22, 2026, 4:45 AM EDT
Terminated No phase listed Observational

Host Genetic Factors Influencing HIV1 and HCV Viral Loads and AIDS Clinical Progression in a Hemophilia Cohort (HGDS-3)

NCT00340548
View directory record Official record
Conditions
Hemophilia, AIDS
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
4 Years to 100 Years
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2020
U.S. locations
15
States / cities
La Jolla, California • Los Angeles, California • Indianapolis, Indiana + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 22, 2026, 4:45 AM EDT
Completed No phase listed Observational

Zepatier in Patients with Substance Use

NCT04048850
View directory record Official record
Conditions
Hepatitis C, Hiv, Coinfection, HIV, Substance Use Disorders
Interventions
Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 22, 2026, 4:45 AM EDT
Completed No phase listed Observational

Study on Immunopathogenesis in HIV and Hepatitis C Coinfection

NCT01296529
View directory record Official record
Conditions
HIV Infection, Hepatitis C Infection, Fibrosis, Inflammation
Interventions
Not listed
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 12, 2012 · Synced Oct 22, 2026, 4:45 AM EDT
Completed Not applicable Interventional

Effects of Sofosbuvir/Ledipasvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir

NCT02588287
View directory record Official record
Conditions
Hepatitis C and HIV Coinfection
Interventions
Blood draws for tenofovir PK, renal function
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Oct 22, 2026, 4:45 AM EDT
Terminated Phase 4 Interventional Results available

Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV

NCT01443923
View directory record Official record
Conditions
Hepatitis, HIV/AIDS
Interventions
Boceprevir, Peg-Interferon-alfa 2B, Ribavirin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 13, 2015 · Synced Oct 22, 2026, 4:45 AM EDT
Completed No phase listed Observational

Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy

NCT00747539
View directory record Official record
Conditions
HIV, Hepatitis C, Infections
Interventions
Pegylated interferon alfa and ribavirin (PEG-IFN/RBV)
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
4
States / cities
Lancaster, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 13, 2016 · Synced Oct 22, 2026, 4:45 AM EDT
Terminated No phase listed Observational Results available

Open Label Study to Evaluate Chronic Hepatitis C Treatment in Latino Subjects With and Without HIV Co-infection

NCT01182298
View directory record Official record
Conditions
Hepatitis C, HIV
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 22, 2026, 4:45 AM EDT
Completed Phase 1 Interventional

Effects of Anti-HIV Drugs on the Hepatitis C Virus (HCV) in Adults Infected With Both HCV and HIV

NCT00545558
View directory record Official record
Conditions
Hepatitis C, HIV Infections
Interventions
Efavirenz, Emtricitabine/Tenofovir disoproxil fumarate
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
2
States / cities
Cincinnati, Ohio • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 12, 2014 · Synced Oct 22, 2026, 4:45 AM EDT
Completed Phase 1 Interventional

Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus

NCT00503347
View directory record Official record
Conditions
Hepatitis C Virus, Hiv Infections
Interventions
bavituximab
Drug
Lead sponsor
Peregrine Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
6
States / cities
Los Angeles, California • Newport Beach, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2011 · Synced Oct 22, 2026, 4:45 AM EDT